Full Text View
Tabular View
No Study Results Posted
Related Studies
Therapy for Infertile PCOS Patients Ovulating Under Clomiphene Citrate or Metformin
This study is currently recruiting participants.
Verified by University Magna Graecia, June 2007
First Received: July 12, 2007   Last Updated: July 16, 2007   History of Changes
Sponsor: University Magna Graecia
Information provided by: University Magna Graecia
ClinicalTrials.gov Identifier: NCT00502229
  Purpose

Several data demonstrated that both clomiphene citrate (CC) and metformin are two safe and valid first-step options to induce ovulation in infertile anovulatory PCOS patients. Notwithstanding a high percentage of patients ovulate under treatment, only ~40% and 60% of subjects obtain a pregnancy after CC and metformin, respectively.

For these patients, controlled ovarian stimulation (COS) followed by intrauterine insemination (IUI) could be the next therapeutic step before assisted reproductive techniques since IUI improves significantly the fertility in couples with unexplained infertility. Furthermore, to date it is not defined if COS should be obtained using the same ovulatory agent (CC or metformin) or switching the treatment to gonadotropins.

In this view, the aim of the present study will be to evaluate the best management of infertile PCOS patients ovulating after CC or metformin.


Condition Intervention Phase
Polycystic Ovary Syndrome
Infertility
Drug: Clomiphene citrate, metformin, highly purified urinary FSH
Phase IV

Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: What is the Following Step to Improve Fertility in Infertile PCOS Patients Ovulating Under Clomiphene Citrate or Metformin? A Randomized Controlled Clinical Study.

Resource links provided by NLM:


Further study details as provided by University Magna Graecia:

Primary Outcome Measures:
  • Pregnancy rate [ Time Frame: one year ]

Secondary Outcome Measures:
  • Ovulation rate Abortion rate Live-birth rate Adverse events [ Time Frame: one year ]

Detailed Description:

Infertile PCOS patients who ovulated under CC or metformin without pregnancy achievement will be enrolled and treated with three trials of COS plus IUI. All patients will be randomly allocated into two different groups (groups A and B). In group A, COS will be obtained using the same ovulatory agent (CC or metformin) employed in the previous ovulatory cycles, whereas in group B using gonadotropins in a low-dose step-up regimen.

All patients eligible will undergo baseline assessment consisting of anthropometric, hormonal, and ultrasonographic evaluations. During the study, the clinical and reproductive outcomes, and the adverse experience will be evaluated and the will be analyzed also categorizing the patients according to ovulatory agent used for COS (CC or metformin).

Data will be analyzed using the intention-to-treat principle and a P value of 0.05 or less will be considered significant. Continuous variables will be analyzed with the unpaired t test and general linear model for repeated measures analysis with Bonferroni test for the post-hoc analysis as required. For categorical variables, the Pearson chi-square and Fisher’s exact tests will be used. Cumulative pregnancy rate, our primary end-point, will be calculated by the Kaplan-Maier method, and the differences between the two groups will be assessed with the log-rank test. Cox proportional-hazards model will be used to calculate the hazard ratio for new pregnancy in both groups.

  Eligibility

Ages Eligible for Study:   18 Years to 35 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Polycystic ovary syndrome (using NIH criteria)
  • Anovulatory infertility (using WHO criteria)

Exclusion Criteria:

  • Age <18 or >35 years
  • Severe obesity (BMI >35)
  • Neoplastic, metabolic, hepatic, and cardiovascular disorders or other concurrent medical illnesses
  • Hypothyroidism, hyperprolactinemia, Cushing’s syndrome, and non-classical congenital adrenal hyperplasia
  • Current or previous (within the last six months) use of oral contraceptives, glucocorticoids, antiandrogens, antidiabetic and anti-obesity drugs or other hormonal drugs
  • Intention to start a diet or a specific program of physical activity
  • Organic pelvic diseases
  • Previous pelvic surgery
  • Suspected peritoneal factor infertility
  • Tubal or male factor infertility or sub-fertility
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00502229

Contacts
Contact: Stefano Palomba, MD +39-0961-883234 stefanopalomba@tin.it

Locations
Italy, Catanzaro, CZ
Pugliese Hospital Recruiting
Catanzaro, Catanzaro, CZ, Italy, 88100
Contact: Ingrid Tomaino, MD     +39-0961-883234     angela.falbo@libero.it    
Sponsors and Collaborators
University Magna Graecia
Investigators
Principal Investigator: Stefano Palomba, MD Department of Obstetrics & Gynecology, University “Magna Graecia” of Catanzaro
Principal Investigator: Francesco Orio, MD Department of Endocrinology, University “Federico II” of Naples
Principal Investigator: Achille Tolino, MD Department of Obstetrics & Gynecology, University “Federico II” of Naples
  More Information

Publications:
Study ID Numbers: 05/2006c
Study First Received: July 12, 2007
Last Updated: July 16, 2007
ClinicalTrials.gov Identifier: NCT00502229     History of Changes
Health Authority: Italy: The Italian Medicines Agency

Keywords provided by University Magna Graecia:
Clomiphene citrate
Controlled overian stimulation
Infertility
Metformin
Polycystic ovary syndrome
Treatment

Additional relevant MeSH terms:
Infertility
Molecular Mechanisms of Pharmacological Action
Gonadal Disorders
Hormone Antagonists
Physiological Effects of Drugs
Hematologic Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Clomiphene
Reproductive Control Agents
Ovarian Diseases
Selective Estrogen Receptor Modulators
Genital Diseases, Female
Estrogen Receptor Modulators
Hypoglycemic Agents
Pathologic Processes
Syndrome
Therapeutic Uses
Estrogen Antagonists
Disease
Anticoagulants
Citric Acid
Metformin
Endocrine System Diseases
Cysts
Genital Diseases, Male
Pharmacologic Actions
Adnexal Diseases
Neoplasms
Fertility Agents, Female
Fertility Agents

ClinicalTrials.gov processed this record on February 08, 2010